Ngm Biopharmaceuticals Inc (NASDAQ: NGM) kicked off on November 20, 2023, at the price of $0.6701, up 4.43% from the previous trading day. During the day, the shares moved up to $0.7342 and dropped to $0.601 before settling in for the closing price of $0.60. Over the past 52 weeks, NGM has traded in a range of $0.60-$5.82.
Healthcare Sector giant saw their annual sales slid by -3.86% over the last five years. While this was happening, its average annual earnings per share was recorded 10.62%. With a float of $44.66 million, this company’s outstanding shares have now reached $81.89 million.
The firm has a total of 239 workers. Let’s measure their productivity. In terms of profitability, gross margin is +89.19, operating margin of -300.45, and the pretax margin is -293.98.
Ngm Biopharmaceuticals Inc (NGM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ngm Biopharmaceuticals Inc is 46.01%, while institutional ownership is 33.00%. The most recent insider transaction that took place on Nov 16, was worth 3,627. In this transaction Director of this company bought 5,840 shares at a rate of $0.62, taking the stock ownership to the 949,862 shares. Before that another transaction happened on Nov 16, when Company’s Director bought 5,840 for $0.62, making the entire transaction worth $3,627. This insider now owns 949,862 shares in total.
Ngm Biopharmaceuticals Inc (NGM) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$0.35 earnings per share (EPS), higher than consensus estimate (set at -$0.42) by $0.07. This company achieved a net margin of -293.98 while generating a return on equity of -54.66. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.62% per share during the next fiscal year.
Ngm Biopharmaceuticals Inc (NASDAQ: NGM) Trading Performance Indicators
Take a look at Ngm Biopharmaceuticals Inc’s (NGM) current performance indicators. Last quarter, stock had a quick ratio of 7.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.84, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.25 in one year’s time.
Technical Analysis of Ngm Biopharmaceuticals Inc (NGM)
Analysing the last 5-days average volume posted by the [Ngm Biopharmaceuticals Inc, NGM], we can find that recorded value of 0.67 million was better than the volume posted last year of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 3.30%. Additionally, its Average True Range was 0.10.
During the past 100 days, Ngm Biopharmaceuticals Inc’s (NGM) raw stochastic average was set at 0.94%, which indicates a significant decrease from 8.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.41% in the past 14 days, which was higher than the 81.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0072, while its 200-day Moving Average is $2.7764. Now, the first resistance to watch is $0.7071. This is followed by the second major resistance level at $0.7872. The third major resistance level sits at $0.8403. If the price goes on to break the first support level at $0.5739, it is likely to go to the next support level at $0.5208. Now, if the price goes above the second support level, the third support stands at $0.4407.
Ngm Biopharmaceuticals Inc (NASDAQ: NGM) Key Stats
The company with the Market Capitalisation of 51.86 million has total of 82,716K Shares Outstanding. Its annual sales at the moment are 55,330 K in contrast with the sum of -162,670 K annual income. Company’s last quarter sales were recorded 580 K and last quarter income was -28,800 K.